Dravet 症候群市场规模、份额和成长分析：按诊断、治疗/管理、类型和地区 - 产业预测，2024-2031 年

2022 年 Dravet 症候群市场规模为 3.4385 亿美元，从 2023 年的 3.7617 亿美元扩大到 2031 年的 7.7184 亿美元，预计在预测期内（2024-2031 年）将以 9.4% 的复合年增长率。

Dravet 综合征，也称为婴幼儿严重肌阵挛性癫痫 (SMEI)，其特征是反覆癫痫发作，通常由发烧或体温升高引发。这种罕见的神经系统疾病通常会持续一生，并从幼儿期开始影响人们。它通常在生命的第一年内发生，最初见于健康婴儿。随着疾病的进展，发作变得更加频繁，其治疗充满挑战和併发症。 Dravet 症候群的独特特征强调了专业医疗照护和对患者及其家人持续支持的至关重要性。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 技术分析
• 价格分析
• 价值链分析
• 市场生态系统
• Start-Ups分析
• 监管环境
• 创新矩阵
• 主要投资分析
• 关键成功因素
• 市场魅力指数
• 竞争程度

Dravet 症候群市场：按诊断

• 市场概况
• 核磁共振检查
• 脑电图测试
• SCN1A测试

Dravet 症候群市场：依治疗与管理分类

• 市场概况
• 癫痫药物
• 生酮饮食
• 迷走神经刺激

Dravet 症候群市场：依类型

• 市场概况
• 製药公司
• 医院
• 诊断实验室
• 学术/研究机构
• 其他的

Dravet 症候群市场：依癫痫类型

• 市场概况
• 肌阵挛发作
• 失张力发作
• 局部性发作
• 失神发作
• 强直阵挛发作
• 光敏性癫痫发作

Dravet 症候群市场规模：依地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• GW Pharmaceuticals plc（United Kingdom）
• Zogenix, Inc.（United States）
• Ovid Therapeutics Inc.（United States）
• Biocodex SA（France）
• Takeda Pharmaceutical Company Limited（Japan）
• PTC Therapeutics, Inc.（United States）
• Epygenix Therapeutics, Inc.（United States）
• Stoke Therapeutics, Inc.（United States）
• UCB SA（Belgium）
• Biscayne Neurotherapeutics, Inc.（United States）
• Anavex Life Sciences Corp.（United States）
• Marinus Pharmaceuticals, Inc.（United States）
• Neurocrine Biosciences, Inc.（United States）
• INSYS Therapeutics, Inc.（United States）
• Otsuka Holdings Co., Ltd.（Japan）
• Aquestive Therapeutics, Inc.（United States）
• Epygenix Therapeutics（United States）
• Eisai Co., Ltd.（Japan）
• Zogenix International Limited（Ireland）
• Tevard Biosciences GmbH（Germany）

Dravet Syndrome Market size was valued at USD 343.85 million in 2022 and is poised to grow from USD 376.17 million in 2023 to USD 771.84 million by 2031, growing at a CAGR of 9.4% in the forecast period (2024-2031).

Dravet syndrome, also called severe myoclonic epilepsy of infancy (SMEI), commonly manifests with recurring seizures often induced by fever or elevated body temperature. This rare neurological condition typically persists throughout life, impacting individuals from early childhood onward. It typically starts within the first year of life and is initially identified in otherwise healthy infants. As the syndrome progresses, seizures become more frequent, posing challenges and complications in its management. The distinct characteristics of Dravet syndrome emphasize the critical need for specialized medical attention and continuous support for both affected individuals and their families.

Top-down and bottom-up approaches were used to estimate and validate the size of the Dravet Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Dravet Syndrome Market Segmental Analysis

The global Dravet Syndrome market is segmented based on diagnosis, treatment & management, type of seizures, end user, and region. Based on diagnosis, the market is segmented into MRI, EEG, SCN1A testing, and others. Based on treatment & management, the market is segmented into Seizure medications, A ketogenic diet, Vagus nerve stimulation, and Others. Based on type of seizures, the market is segmented into Myoclonic Seizures, Atonic Seizures, Absence Seizures, Photosensitive Seizures, Partial Seizures, and Others. Based on end user, the market is segmented into Pharmaceutical companies, hospitals, diagnostic laboratories, academic & research institutes, and others. Based on region, the market is segmented into North America, Europe, Asia-Pacific Latin America, and Middle East & Africa.

Drivers of the Dravet Syndrome Market

Genetic mutations, particularly those involving the SCN1A gene, are a major factor in triggering Dravet syndrome in children, with around 80-90% of cases linked to mutations in this specific gene. Advances in genetic testing technology are anticipated to boost market revenue for testing methods. Sophisticated diagnostic approaches such as dual detection, deletion analysis, and mosaicism testing are crucial for accurately and efficiently diagnosing genetic abnormalities associated with Dravet syndrome. These advancements promise to enhance diagnostic precision and contribute to improved patient care outcomes.

Restraints in the Dravet Syndrome Market

The projected revenue growth for Dravet Syndrome could encounter challenges due to several factors. Epilepsy and related seizure disorders have historically been surrounded by societal stigma, discrimination, misinformation, and fear on a global scale. This pervasive stigma linked with the condition may discourage individuals from seeking treatment, as they may fear the consequences of being associated with such a diagnosis. This could potentially hinder efforts to effectively address and manage the condition.

Market Trends of the Dravet Syndrome Market

Recent advancements in regulatory approvals have significantly propelled efforts in managing Dravet Syndrome. Particularly, the approval of medications like stiripentol (Diacomit) and Epidiolex has proven instrumental in treating symptoms associated with the disorder. These regulatory milestones represent significant progress in addressing the severe complexities of Dravet syndrome. Additionally, anticipation of forthcoming regulatory approvals, such as Zogenix's submission of a New Drug Application (NDA) for its clinical candidate ZX008 (Fintepla), is poised to further accelerate market growth.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Start-up Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Market Attractive Index
• Degree of Competition

Global Dravet Syndrome Market by Diagnosis

• Market Overview
• MRI Testing
• EEG Testing
• SCN1A Testing

Global Dravet Syndrome Market by Treatment & Management

• Market Overview
• Seizure medications
• A ketogenic diet
• Vagus nerve stimulation

Global Dravet Syndrome Market by Type

• Market Overview
• Pharmaceutical Companies
• Hospitals
• Diagnostic Laboratories
• Academic & research institutes
• Others

Global Dravet Syndrome Market by Type of Seizures

• Market Overview
• Myoclonic Seizures
• Atonic Seizures
• Partial Seizures
• Absence Seizures
• Tonic Clonic Seizures
• Photosensitive Seizures

Global Dravet Syndrome Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• GW Pharmaceuticals plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zogenix, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ovid Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocodex S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PTC Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epygenix Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stoke Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biscayne Neurotherapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anavex Life Sciences Corp. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Marinus Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurocrine Biosciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• INSYS Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aquestive Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epygenix Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zogenix International Limited (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tevard Biosciences GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments